SELF-REPORT CREDIT FORM

Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The Johns Hopkins University School of Medicine and the National Institutes of Health. The Johns Hopkins University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement:
The Johns Hopkins University School of Medicine designates this educational activity for 1 credit per session for a maximum of 44 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Clinical Center Grand Rounds
Lipsett Amphitheater
12 Noon – 1 p.m.
December 15, 2010

Principles of Pharmacogenomics and Its Applications in Clinical Practice
David A. Flockhart, M.D., Ph.D., Chief, Division of Clinical Pharmacology, Department of Medicine
Professor of Medicine, Medical Genetics, and Pharmacology, Indiana University School of Medicine

Applications of Pharmacogenomics in Drug Development and Regulatory Review
Shiew-Mei Huang, Ph.D. Deputy Director, Office of Clinical Pharmacology, Food and Drug Administration

NOTE: To receive credit for attendance, this form must be returned to the Office of Clinical Research Training and Medical Education by 4 pm on the day of the lecture. Please fax forms to 301-435-5275. For CC Grand Rounds CME inquiries, contact Avril Bertrand at 301-496-9425 or bertranda@cc.nih.gov

<table>
<thead>
<tr>
<th>Date(s)</th>
<th>Maximum Approved Hours per session/per week</th>
<th>Earned Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>December 15, 2010</td>
<td>1 hour per session/per week</td>
<td>1.0*</td>
</tr>
</tbody>
</table>

Please Print Clearly
Please check one: _____Physician _____Non-Physician

NAME - LAST
FIRST
MI
PROFESSIONAL DEGREE

NIH BADGE NUMBER (IF NIH EMPLOYEE)

PHONE
EMAIL
ORGANIZATION
INSTITUTE/CENTER
DEPT/BRANCH

ADDRESS
CITY
STATE
ZIP + 4

SIGNATURE REQUIRED for ALL ATTENDEES:
I attest that the above number credit hour(s) is correct.

X__________________________________________________________ ___________________
Signature of Attendee Date

*These hours will be verified by the Office of Continuing Medical Education (OCME) and recorded on your official Transcript.
Please complete the Continuing Medical Education Questionnaire. To indicate your answers, use the rating scale that is shown by circling the number that represents your answer.

Scale:
1 - None or Not at all  2 - Very little  3 – Moderately  4 – Considerably  5 – Completely  N/A - Not applicable

Speaker: David A. Flockhart, M.D., Ph.D.

Objective: To use clinical pharmacogenomics in making strategic research and clinical decisions

A. Rating of Objectives and Activity

1. Please rate the attainment of objectives:
   a. Define options and alternatives that will guide clinical practice 1 2 3 4 5 N/A
   b. Evaluate practical information about clinical research principles based on state-of-the-art information about scientific discovery and clinical advances 1 2 3 4 5 N/A
   c. Analyze information and opportunities to increase and improve collaboration between investigators 1 2 3 4 5 N/A

2. The overall quality of the instructional process was an asset to the activity: 1 2 3 4 5 N/A

3. To what extent did participation in this activity enhance your professional effectiveness? 1 2 3 4 5 N/A

4. Will you change your practice in any way as a result of attending this activity? 1 2 3 4 5 N/A

5. Did you perceive any commercial bias?
   Use the following criteria to judge?
   a) The content presented was balanced, evidence-based, demonstrated scientific rigor, and was without commercial bias. ____No  ____Yes
      If no, please specify: ________________________________
   b) I was informed about the existence and resolution of relevant financial relationships/conflicts of interests of planners and presenters prior to the presentation. ____No  ____Yes
      If no, please specify: ________________________________
   c) Speakers who discussed off-label, investigational, or alternative uses of products, devices, or techniques disclosed this in their presentation. ____No  ____Yes
      If no, please specify: ________________________________

B. Comments:

1. What comments or suggestions do you have for the faculty presenter(s)?
   ___________________________________________

2. Are there any other speakers or new topics you would like to have covered in this or a related activity?
   ___________________________________________

3. Do you have additional comments to enhance the utility or impact of the activity?
   ___________________________________________

4. May we contact you in several weeks’ time with a very brief survey to assess the usefulness of this CME activity? ___Yes  ___No  If yes, please provide your email: __________________________
Please complete the Continuing Medical Education Questionnaire. To indicate your answers, use the rating scale that is shown by circling the number that represents your answer.

Scale:
1 - None or Not at all  2 - Very little  3 – Moderately  4 – Considerably  5 – Completely  N/A - Not applicable

Speaker: Shiew-Mei Huang, Ph.D.

Objective: To be aware of recent relabeling of drug products to include relevant genetic/genomic information and to understand the scientific basis of these relabeling activities.

A. Rating of Objectives and Activity

5. Please rate the attainment of objectives:
   a. Define options and alternatives that will guide clinical practice 1 2 3 4 5 N/A
   b. Evaluate practical information about clinical research principles based on state-of-the-art information about scientific discovery and clinical advances 1 2 3 4 5 N/A
   c. Analyze information and opportunities to increase and improve collaboration between investigators 1 2 3 4 5 N/A

6. The overall quality of the instructional process was an asset to the activity: 1 2 3 4 5 N/A

7. To what extent did participation in this activity enhance your professional effectiveness? 1 2 3 4 5 N/A

4. Will you change your practice in any way as a result of attending this activity? 1 2 3 4 5 N/A

5. Did you perceive any commercial bias?
   Use the following criteria to judge?

   b) The content presented was balanced, evidence-based, demonstrated scientific rigor, and was without commercial bias. ___No  ___Yes
      If no, please specify: ________________________________

   b) I was informed about the existence and resolution of relevant financial relationships/conflicts of interests of planners and presenters prior to the presentation. ___No  ___Yes
      If no, please specify: ________________________________

   c) Speakers who discussed off-label, investigational, or alternative uses of products, devices, or techniques disclosed this in their presentation. ___No  ___Yes
      If no, please specify: ________________________________

B. Comments:

1. What comments or suggestions do you have for the faculty presenter(s)?
   ________________________________________________________________

2. Are there any other speakers or new topics you would like to have covered in this or a related activity?
   ________________________________________________________________

3. Do you have additional comments to enhance the utility or impact of the activity?
   ________________________________________________________________

8. May we contact you in several week’s time with a very brief survey to assess the usefulness of this CME activity? ___Yes  ___No  If yes, please provide your email: __________________________